Journal of Clinical and Aesthetic Dermatology

APR 2018

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: https://jcadonline.epubxp.com/i/959274

Contents of this Issue

Navigation

Page 2 of 61

Your patients on commercial insurance can now access Otezla without any biologic step-edit requirements on: GETTING OTEZLA GETS EVEN EASIER Contact your Otezla representative or visit otezlapro.com for a complete list of plans Contact your Otezla representative or visit otezlapro.com for a complete list of plans *SafeGuardRx SM Program has 1 biologic step for patients on certain Otezla indications. DMARD, disease-modifying antirheumatic drug. Reference: 1. Data on file, Celgene Corporation. Aetna Prescription Drug Benefit Cigna Prescription Drug List CVS Caremark Basic and Standard Control Formularies Express Scripts National Preferred Formulary* OptumRx Prime Therapeutics UnitedHealthcare No DMARD or biologic step-edit required 8 out of 10 commercially insured lives in the US have preferred access with no biologic step required for Otezla® (apremilast) 1 Otezla® is a registered trademark of Celgene Corporation. © 2018 Celgene Corporation 01/18 USII-APR170526

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - APR 2018